Chordia Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Hiroshi Miyake

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	7.1yrs
CEO ownership	1.3%
Management average tenure	no data
Board average tenure	2.1yrs

Recent management updates

No updates

Recent updates

We're Hopeful That Chordia Therapeutics (TSE:190A) Will Use Its Cash Wisely

Dec 19

CEO

Hiroshi Miyake (54 yo)

7.1yrs

Tenure

Mr. Hiroshi Miyake, Ph D., is Co-Founder of Chordia Therapeutics Inc. and serves as its Chief Executive Officer and Representative Director since November 2017 and serves as its Chairman. He has experience...

Board Members

Name	Position	Tenure	Compensation	Ownership
Hiroshi Miyake	Co-Founder	7.1yrs	no data	1.33% ¥ 285.3m
Akihiko Shimauchi	Independent External Director	2.2yrs	no data	no data
Kosuke Ishii	Independent External Director	2.1yrs	no data	no data
Ayuko Hashimoto	Independent External Director	2.1yrs	no data	no data
Yukari Nishikata	Independent External Director	2.1yrs	no data	no data
Manabu Nakamura	Independent Outside Director	less than a year	no data	no data

2.1yrs

Average Tenure

55yo

Average Age

Experienced Board: 190A's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 18:30
End of Day Share Price	2024/12/27 00:00
Earnings	2024/08/31
Annual Earnings	2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chordia Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution